Skip to Content

Hydrochlorothiazide / losartan Side Effects

Not all side effects for hydrochlorothiazide / losartan may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to hydrochlorothiazide / losartan: oral tablet

In addition to its needed effects, some unwanted effects may be caused by hydrochlorothiazide / losartan. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking hydrochlorothiazide / losartan:

Symptoms of fluid and electrolyte imbalance
  • Dry mouth
  • increased thirst
  • muscle cramps or pain
  • nausea or vomiting
  • unusual tiredness or weakness
  • weak or irregular heartbeat
  • Black, tarry stools
  • blood in the urine or stools
  • cough or hoarseness accompanied by chills or fever, lower back or side pain, or painful or difficult urination
  • fainting
  • pinpoint red spots on the skin
  • pounding heartbeat
  • severe stomach pain, nausea, and vomiting
  • skin rash
  • swelling of the feet or lower legs
  • unusual bleeding or bruising
Incidence not known
  • Coma
  • confusion
  • convulsions
  • dark-colored urine
  • decreased urine output
  • fast or irregular heartbeat
  • fever
  • irritability
  • large, flat, blue, or purplish patches in the skin
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • light-colored stools
  • muscle spasms
  • muscle stiffness
  • muscle twitching
  • painful knees and ankles
  • raised red swellings on the skin, the buttocks, legs or ankles
  • restlessness
  • seizures
  • shortness of breath
  • swelling of the face, ankles, or hands
  • upper right abdominal or stomach pain
  • weakness
  • yellow eyes and skin

Some of the side effects that can occur with hydrochlorothiazide / losartan may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Cold or flu-like symptoms
  • dizziness
  • headache
  • increased sensitivity of the skin to sunlight
  • sore throat
  • stomach pain
  • Dry cough
  • sinus problems

For Healthcare Professionals

Applies to hydrochlorothiazide / losartan: oral tablet


Hydrochlorothiazide-losartan is generally well-tolerated. The overall incidence of adverse experiences reported with losartan monotherapy appears to be similar to placebo. For the most part, side effects associated with the combination drug are transient and mild. In controlled clinical trials, discontinuation of therapy due to adverse drug events has been reported in 2.5% and 2.3% of patients treated with the combination and placebo, respectively.

General side effects reported postmarketing have included malaise thought to be related to the losartan component.[Ref]


Since HCTZ may increase total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%, and since it may reduce insulin secretion, it should be used with caution in patients with hypercholesterolemia and/or diabetes.

HCTZ-induced hyperuricemia may be an important consideration in patients with a history of gout. Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.[Ref]

Metabolic side effects associated with HCTZ are more commonly associated with daily HCTZ doses of 50 mg or more, which are not recommended with the combination product. These side effects may occur at lower doses, however, and include mild hypokalemia (decrease of 0.5 mEq/L), metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, hypercholesterolemia and elevated serum uric acid levels.[Ref]


Hypersensitivity reactions typically present as nausea, vomiting, diarrhea, and rash, and are probably due to the HCTZ component. Hypersensitivity is reported in less than 1% of patients. Cases of acute pulmonary edema, interstitial cystitis or nephritis, and anaphylaxis have also been associated with HCTZ.[Ref]


Cardiovascular side effects associated with losartan include dizziness in 5.7% (vs. 2.9% in placebo-treated subjects) and orthostatic hypotension. Rarely, HCTZ-induced hypokalemia or hyponatremia have been associated with significant cardiac arrhythmias including ventricular ectopy and complete AV heart block. Hypokalemia is much less likely with the combination drug, however, since losartan inhibits aldosterone secretion. Fingernail clubbing has also been associated with the use of losartan. In addition, angioneurotic edema has been reported during losartan therapy.[Ref]

Nervous system

Nervous system side effects associated with losartan include headache in up to 14%, asthenia/fatigue in 4%, insomnia in 1% of patients, and rare cases of ageusia (altered tasted) and migraine headache. Rare cases of cerebrovascular insufficiency have been associated with HCTZ induced plasma volume contraction. Dysgeusia has been reported with losartan in postmarketing experience.[Ref]


A 67-year-old white woman with hypothyroidism, hypercalcemia, depression, and hypertension developed facial erythema, headaches, tremors, confusion, and personality changes associated with a new positive ANA and anti-nRNP and a skin biopsy consistent with lupus erythematosus while taking HCTZ, levothyroxine, and amitriptyline. The eruption resolved upon discontinuation of HCTZ, but she later developed a higher ANA titer associated with symptomatic diffuse interstitial pulmonary infiltrates. She was successfully treated with corticosteroids.[Ref]

Dermatologic reactions associated with HCTZ include erythema annular centrifugum, acute eczematous dermatitis, and morbilliform or leukocytoclastic vasculitis. Thiazides may induce phototoxic dermatitis. In addition, a rare, distinct entity with clinical and laboratory features indistinguishable from those of subacute cutaneous lupus erythematosus has been associated with HCTZ. Erythroderma has been reported with losartan in postmarketing experience.[Ref]


Renal side effects including new or worsened renal insufficiency may occur due to HCTZ-induced intravascular volume depletion. Rare cases of interstitial nephritis have been associated with HCTZ. Decreased renal function or hyperkalemia has only rarely been associated with losartan, although experience with this drug is limited compared with the related compounds, the ACE inhibitors. The effects of losartan and ACE inhibitors on renal hemodynamics and kidney function are similar. In addition, acute renal failure associated with losartan therapy has been reported in at least one patient with bilateral renal artery stenosis.[Ref]

The increase in plasma renin activity associated with losartan is relatively small compared with those increases associated with ACE inhibitors. These blunted increases do not appear to affect the antihypertensive response to the antagonist.

In one study of patients with significant proteinuria and moderate renal insufficiency (average creatinine clearance > 60 mL/min), losartan 50 to 100 mg/day was associated with significantly increased renal plasma flow and significantly decreased urinary excretion of total protein, albumin, and immunoglobulin.

Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case in which the drug was believed to have caused this condition has been reported.[Ref]


Gastrointestinal complaints have been reported in less than 2% of patients, and have included loose bowel movements, dyspepsia, epigastric discomfort, and nausea. Rare cases of pancreatitis and acute cholecystitis have been associated with HCTZ. Dysgeusia, ageusia, and oral ulcers associated with losartan therapy have been rarely reported. Acute pancreatitis has also been associated with losartan use.[Ref]

Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in increased risk of cholesterol gallstone formation. Reports of bowel strictures associated with thiazide ingestion were reported in the 1960's, although these patients were on a combination HCTZ-potassium product.[Ref]


Respiratory system side effects are rare. Cough has been reported in 3.4% of treated patients and 3.3% of patients taking placebo. One comparative study has shown that losartan reduces coughing in patients who have a history of cough associated with ACE inhibitors. However, cases of cough, including rechallenge, have been associated with losartan use in postmarketing research. Nasal congestion has been reported in 1% to 2% of patients. Approximately 30 cases of acute noncardiogenic pulmonary edema have been associated with thiazide diuretics. These cases have been thought to be due to idiosyncrasy or a hypersensitivity mechanism.[Ref]


Musculoskeletal side effects including back or leg pain have been reported in approximately 1% of patients, compared to 0% with placebo. In addition, rare reports of rhabdomyolysis have been reported during postmarketing experience in patients receiving angiotensin II receptor blockers.[Ref]


Immunologic side effects are rare, and include cases of allergic vasculitis and hemolytic anemia associated with HCTZ. A case of Henoch-Schonlein purpura with a high titer of x-specific antineutrophil cytoplasmic antibodies (xANCA) has been associated with losartan therapy.[Ref]


Hematologic side effects are rare. Cases of immune-complex hemolytic anemia, aplastic anemia, and thrombocytopenia have been associated with HCTZ. Hematologic side effects associated with losartan have included reports of small decreases in hemoglobin and hematocrit in which no patients were discontinued due to anemia. In addition, anemia has been reported in renal transplant recipients (not having posttransplant erythrocytosis) treated with losartan. Losartan has also been implicated in a case of immune thrombocytopenia. Thrombocytopenia has also been noted in postmarketing experience with losartan.[Ref]


A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed an increased mean fasting blood glucose level after treatment. Withdrawal of thiazide therapy for 7 months in 10 of the patients resulted in mean reductions of 10% in the average fasting blood glucose value and 25% in the average 2-hour glucose tolerance test value. A control group was not reported.[Ref]

Endocrinologic problems associated with thiazide diuretics include glucose intolerance and a potentially deleterious effect on the lipid profile. This may be important in some patients with or who are at risk for diabetes or coronary artery disease.[Ref]


Hepatic side effects including increases in hepatic enzymes and serum bilirubin have been reported only occasionally with losartan. Less than 0.1% of patients from large-scale controlled trials discontinued losartan therapy due to increased liver function tests. Hepatitis has been reported rarely with losartan therapy.[Ref]


Ocular side effects have included idiosyncratic reactions to the hydrochlorothiazide component resulting in acute transient myopia and acute angle-closure glaucoma.


1. F-D-C Reports, Inc. "Merck Cozaar antihypertensive approved april 14: labeling appears to suport Merck's claim of clean side-effect profile for first angiotensin II inhibitor." F-D-C Reports -- "The Pink Sheet" 57 (1995): 22

2. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD "Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers." Hypertension 21 (1993): 704-13

3. Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." Clin Ther 18 (1996): 608-25

4. Hoss DM, Nierenberg DW "Severe shaking chills and fever following hydrochlorothiazide administration." Am J Med 85 (1988): 747

5. Schoenberger JA "Losartan with hydrochlorothiazide in the treatment of hypertension." J Hypertens 13 Suppl (1995): s43-7

6. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Miettinen OS, Stolley PD "Thiazides and acute cholecystitis." N Engl J Med 303 (1980): 546-8

7. Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995): 223-6

8. Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990): 739-42

9. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988): 380-5

10. Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986): 341

11. Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987): 143-8

12. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991): 165-8

13. Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 48

14. Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980): 1975-6

15. Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986): 1456-7

16. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5

17. Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2

18. Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986): 634

19. Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989): 966-9,

20. Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981): 67-73

21. Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983): 283-96

22. Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981): 80-3

23. Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985): 1045-59

24. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,

25. Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971): 828-30

26. Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995): 133-41

27. Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985): 595-9

28. Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10

29. Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983): 1017-22

30. Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988): 329-31

31. Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979): 591-4

32. Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971): 853-63

33. Mackay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS "Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components." Arch Intern Med 156 (1996): 278-85

34. Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 175-6

35. Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73

36. Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990): 704-8

37. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A "Non-cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide ." Intensive Care Med 13 (1987): 364-5

38. Hoegholm A, Rasmussen SW, Kristensen KS "Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction." Br Heart J 63 (1990): 186

39. Levay ID "Hydrochlorothiazide-induced pulmonary edema." Drug Intell Clin Pharm 18 (1984): 238-9

40. Dorn MR, Walker BK "Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy." Chest 79 (1981): 482-3

41. Klein MD "Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion." Ann Emerg Med 16 (1987): 901-3

42. Beaudry C, Laplante L "Severe allergic pneumonitis from hydrochlorothiazide." Ann Intern Med 78 (1973): 251-3

43. Goette DK, Beatrice E "Erythema annulare centrifugum caused by hydrochlorothiazide-induced interstitial nephritis." Int J Dermatol 27 (1988): 129-30

44. Grunwald MH, Halevy S, Livni E "Allergic vasculitis induced by hydrochlorothiazide: confirmation by mast cell degranulation test." Isr J Med Sci 25 (1989): 572-4

45. Biron P, Dessureault J, Napke E "Acute allergic interstitial pneumonitis induced by hydrochlorothiazide [published erratum appears in Can Med Assoc J 1991 Sep 1;145(5):391]." Can Med Assoc J 145 (1991): 28-34

46. Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980): 939-43

47. Prupas HM, Brown D "Acute idiosyncratic reaction to hydrochlorothiazide ingestion." West J Med 138 (1983): 101-2

48. Grace AA, Morgan AD, Strickland NH "Hydrochlorothiazide causing unexplained pulmonary oedema." Br J Clin Pract 43 (1989): 79-81

49. Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983): 36-41

50. Soffer BA, Wright JT, Howard J, Pratt JH, Wiens B, Goldberg AI, Sweet CS "Effects of losartan on a background of hydrochlorothiazide in patients with hypertension." Hypertension 26 (1995): 112-7

51. Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T "Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure." J Hypertens Suppl 12 (1994): s31-5

52. Goldberg AI, Dunlay MC, Sweet CS "Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension." Am J Cardiol 75 (1995): 793-5

53. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al "Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group." Circulation 91 (1995): 691-7

54. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al "Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients." Hypertension 25 (1995): 37-46

55. Rush JE, Rajfer SI "Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure." J Hypertens 11 Suppl 3 (1993): s69-71

56. Weir MR, Wright JT, Jr Ferdinand KC, Cook CA, Champion D, Wong S, Jenkins PA, Kong BW "Comparison of the efficacy and metabolic effects of nicardipine and hydrochlorothiazide in hypertensive black men and women." J Hum Hypertens 7 (1993): 141-7

57. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS "A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension." Hypertension 25 (1995): 1345-50

58. Dahlof B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY "Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension." Am J Hypertens 8 (1995): 578-83

59. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL "Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man." J Cardiovasc Pharmacol 21 (1993): 732-8

60. "Product Information. Hyzaar (losartan-hydrochlorothiazide)." Merck & Co, Inc, West Point, PA.

61. Schlienger RG, Saxer M, Haefeli WE "Reversible ageusia associated with losartan." Lancet 347 (1996): 471-2

62. Schaefer KL, Porter JA "Angiotensin II receptor antagonists: the prototype losartan." Ann Pharmacother 30 (1996): 625-36

63. Weber MA, Bryyny RL, Pratt JH, et al. "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995): 405-11

64. Critchley JAJH, Gilchrist N, Ikeda L, Dubois C, Bradstreet DC, Shaw WC, Goldberg AI, Sweet CS "A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide versus captopril and hydrochlorothiazide in elderly and younger patients." Curr Ther Res Clin Exp 57 (1996): 392-407

65. Diffey BL, Langtry J "Phototoxic potential of thiazide diuretics in normal subjects." Arch Dermatol 125 (1989): 1355-8

66. Robinson HN, Morison WL, Hood AF "Thiazide diuretic therapy and chronic photosensitivity." Arch Dermatol 121 (1985): 522-4

67. Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989): 100-2

68. Bjornberg A, Gisslen H "Thiazides: A cause of necrotising vasculitis?" Lancet 2 (1965): 982-3

69. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985): 49-51

70. Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993): 1001-2

71. Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973): 992

72. Ardaillou R, Chansel D "Glomerular effects of angiotensin II: a reappraisal based on studies with non-peptide receptor antagonists." J Hypertens 11 Suppl 3 (1993): s43-7

73. Cohen LS, Friedman EA "Losartan-induced azotemia in a diabetic recipient of a kidney transplant." N Engl J Med 334 (1996): 1271-2

74. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB "Blood pressure effects of the angiotensin II receptor blocker, losartan." Arch Intern Med 155 (1995): 405-11

75. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K "Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension [published erratum appears in Am J Hypertens 1993 May;6(5 Pt 1):451]." Am J Hypertens 6 (1993): 28-32

76. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE "Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease." J Hypertens Suppl 12 (1994): s37-42

77. Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966): 291-6

78. Smith BL, Tedeschi A, Lane CD "Pancreatitis with a twist." Hosp Pract (Off Ed) 23 (1988): 150,

79. Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965): 383-5

80. Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11

81. Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101

82. Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8

83. Karlberg BE "Cough and inhibition of the renin-angiotensin system." J Hypertens 11 Suppl 3 (1993): s49-52

84. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM "Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia." Transfusion 28 (1988): 70-2

85. Beck ML, Cline JF, Hardman JT, Racela LS, Davis JW "Fatal intravascular immune hemolysis induced by hydrochlorothiazide." Am J Clin Pathol 81 (1984): 791-4

86. Garratty G, Houston M, Petz LD, Webb M "Acute immune intravascular hemolysis due to hydrochlorothiazide." Am J Clin Pathol 76 (1981): 73-8

87. Eisner EV, Crowell EB "Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody." JAMA 215 (1971): 480-2

88. Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973): 1238-9

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.